These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3191361)

  • 1. Bone mineral content in patients with carcinoma of the prostate.
    Mobb GE; Moisey CU; Ring EF
    Br J Urol; 1988 Oct; 62(4):355-8. PubMed ID: 3191361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone imaging and serum phosphatases in prostatic carcinoma.
    Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
    Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis.
    de la Piedra C; Torres R; Rapado A; Diaz Curiel M; Castro N
    Calcif Tissue Int; 1989 Jul; 45(1):58-60. PubMed ID: 2504465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineral content of skeletal bones in otosclerosis.
    Jensen KJ; Nielsen HE; Elbrønd O; Hansen HH
    Clin Otolaryngol Allied Sci; 1979 Oct; 4(5):339-42. PubMed ID: 487632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
    Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
    Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
    [No Abstract]   [Full Text] [Related]  

  • 6. Adrenal suppression in the treatment of carcinoma of the prostate.
    Robinson MR; Shearer RJ; Fergusson JD
    Br J Urol; 1974 Oct; 46(5):555-9. PubMed ID: 4422260
    [No Abstract]   [Full Text] [Related]  

  • 7. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyproterone acetate in the treatment of advanced carcinoma of the prostate.
    Smith RB; Walsh PC; Goodwin WE
    J Urol; 1973 Jul; 110(1):106-8. PubMed ID: 4713345
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone mineral status in childhood accidental fractures.
    Chan GM; Hess M; Hollis J; Book LS
    Am J Dis Child; 1984 Jun; 138(6):569-70. PubMed ID: 6720643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral content in renal transplant patients.
    Nielsen HE
    Clin Nephrol; 1978 Nov; 10(5):196-200. PubMed ID: 365405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer.
    Buchs N; Bonjour JP; Rizzoli R
    J Clin Endocrinol Metab; 1998 May; 83(5):1535-41. PubMed ID: 9589651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
    Merrick MV; Ding CL; Chisholm GD; Elton RA
    Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer.
    Gotfredsen A; Christiansen C; Palshof T
    Cancer; 1984 Feb; 53(4):853-7. PubMed ID: 6692287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
    Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
    Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical picture accompanying sclerotic bone metastases of prostatic origin.
    Minisola S; Perugia G; Scarda A; Scarnecchia L; Tuzzolo D; Rossi W; Mazzuoli G
    Br J Urol; 1987 Nov; 60(5):443-6. PubMed ID: 3427318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral content in normally menstruating women with hyperprolactinaemia.
    Nyström E; Leman J; Lundberg PA; Lindquist O; Hansson T; Bengtsson C; Rybo G; Lindstedt G
    Horm Res; 1988; 29(5-6):214-7. PubMed ID: 3220459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.